Overview
- Provides a unique attempt to make a bridge between human microbiome and real protocols for medical practice
- Offers a new vision on human microbiome data as an instrument of personal health and disease balance
- Summarizing probiotics efficacy data within the prism of 3P medicine approach
Part of the book series: Advances in Predictive, Preventive and Personalised Medicine (APPPM, volume 16)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (15 chapters)
Keywords
About this book
The book analyses microbiome-relevant findings focused on clinical needs providing the roadmap to implement recent achievements in the area representing a valuable contribution to the paradigm shift from reactive to predictive, preventive and personalised medicine (PPPM / 3PM) considered as the most advanced concept in medicine.
Already well-acknowledged as well as future advantages of application of pre-, pro- and pharma-biotics are detailed in the book.
Socio-economic impacts of the area are considered in the context of the entire spectrum of healthcare services from disease care provided to patients up to health care provided to persons in suboptimal health conditions.
Innovative technologies including phenotyping, genotyping, individualised profiling, patient stratification, big data analysis, and multi-omics, amongst others are all involved in the book.
The book is unique from view point of multi-professional expertise involved. International network presents more than 10 countries worldwide including Belgium, China, Germany, Israel, Ukraine and USA. The data presented are of great scientific value and of particular importance for educating a broad spectrum of professionals including researchers, healthcare givers, policy makers, business people, policy makers and general population.
Editors and Affiliations
About the editors
She is dealing with a lot of national and international groups of contacts on regular bases and participating as p.i. in around 40 projects. She is also the author of about 350 scientific works, including 100 papers in professional scientific journals, more than 50 publications in the peer-reviewed journals, and Chapter in Elsevier press, index H=12. She is specialist with expertise in life sciences, participated in international projects like BaSeFood, JSO-ERA EU – FP7, CAPINFOOD (SEE), BacFoodNet (COST), ODiN (FP7), FoodWARD (Erasmus) and H2020 (SKIN) projects.
Prof. Dr. Golubnitschaja is the head of the world first Predictive, Preventive Personalised (3P) Medicine unit at the Department of Radiation Oncology, University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany. She is educated in journalism, biotechnology and medicine and has been awarded research fellowships in Austria, Russia, UK, Germany, Netherlands, and Switzerland (early and predictive diagnostics in paediatrics, neurosciences and cancers).
Dr. Golubnitschaja is the author of more than 400 international publications (research and review articles, position papers, books, book and congress contributions) in the innovative field of predictive, preventive and personalised medicine (3PM) with the main research focuses on sub-optimal health conditions, pre- and perinatal diagnostics, diagnostics of cardiovascular disease and neurodegenerative pathologies, predictive diagnostics in cancer and diabetes. In 1990-2002 she published as Olga Labudova. Cumulative Google Scholar h-index is 60.
Awards: National & International Fellowship of theAlexander von Humboldt-Foundation; Highest Prize in Medicine and Eiselsberg-Prize in Austria; Springer-Nature Award; EMA Award.
In years 2009 – 2021 Dr. Golubnitschaja was the Secretary-General and since September 2021 she is the President of the “European Association for Predictive, Preventive & Personalised Medicine” (EPMA, Brussels) networking over 50 countries worldwide. She is Editor-in-Chief of the EPMA J. (actual Clarivate IF 6.543, Scopus CiteScore 11.3) and Editor-in-Chief of the Book Series “Advances in Predictive, Preventive & Personalised Medicine”, Springer Nature.
Dr. Golubnitschaja is the European Representative in the EDR-Network at the National Institutes of Health USA. She acts as a regular reviewer in over 50 clinical and scientific journals and as a grant reviewer of inter/national funding bodies in European and other countries.
Dr. Golubnitschaja is an evaluation expert at the European Commission. In years 2010-2013 she was involved in creating the PPPM related contents of the European Programme “Horizon 2020”. Currently, She is Vice-Chair of the Habilitation Committee (responsible for all medical specialisations) at the Medical Faculty, University of Bonn, Germany and is Vice-Chair of the Evaluation Panel for Marie Curie Mobility Actions at the European Commission in Brussels.Bibliographic Information
Book Title: Microbiome in 3P Medicine Strategies
Book Subtitle: The First Exploitation Guide
Editors: Nadiya Boyko, Olga Golubnitschaja
Series Title: Advances in Predictive, Preventive and Personalised Medicine
DOI: https://doi.org/10.1007/978-3-031-19564-8
Publisher: Springer Cham
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2023
Hardcover ISBN: 978-3-031-19563-1Published: 03 February 2023
Softcover ISBN: 978-3-031-19566-2Published: 03 February 2024
eBook ISBN: 978-3-031-19564-8Published: 02 February 2023
Series ISSN: 2211-3495
Series E-ISSN: 2211-3509
Edition Number: 1
Number of Pages: XV, 425
Number of Illustrations: 1 b/w illustrations
Topics: Medical Microbiology, Health Informatics, Metabolic Diseases